English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing.

MPS-Authors
/persons/resource/persons15362

Konrad,  M.
Research Group of Enzyme Biochemistry, MPI for biophysical chemistry, Max Planck Society;

Fulltext (public)

1938019.pdf
(Publisher version), 3MB

Supplementary Material (public)
There is no public supplementary material available
Citation

McSorley, T., Ort, S., Monnerjahn, C., & Konrad, M. (2014). A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing. Biochemical Pharmacology, 87(3), 435-444. doi:10.1016/j.bcp.2013.11.011.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0015-8268-F
Abstract
The limitations of the ganciclovir (GCV)/herpes simplex virus thymidine kinase (HSV1 TK: EC 2.7.1.21) system as a suicide gene therapy approach have been extensively studied over the years. In our study, we focused on improving the cytotoxic profile of the GCV/equine herpes virus-4 thymidine kinase (EHV4 TK: EC 2.7.1.21) system. Our approach involved the structure-guided mutagenesis of EHV4 TK in order to switch its ability to preferentially phosphorylate the natural substrate deoxythymidine (dT) to that of GCV. We performed steady-state kinetic analysis, genetic complementation in a thymidine kinase-deficient Escherichia coli strain, isothermal titration calorimetry, and analysis of GCV-induced cell killing through generation of HEK 293 stable cell-lines expressing EHV4 TK mutants and wild-type EHV4 TK. We found that the EHV4 TK S144H-GFP mutant preferentially phosphorylates GCV and confers increased GCV-induced cytotoxicity compared to wild-type EHV4 TK.